<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>312</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10543973</PubmedId>
            <Abstract>The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEGF) to vascular endothelial growth factor (VEGF) has been affinity-matured through complementarity-determining region (CDR) mutation, followed by affinity selection using monovalent phage display. After stringent binding selections at 37 degrees C, with dissociation (off-rate) selection periods of several days, high affinity variants were isolated from CDR-H1, H2, and H3 libraries. Mutations were combined to obtain cumulatively tighter-binding variants. The final variant identified here, Y0317, contained six mutations from the parental antibody. In vitro cell-based assays show that four mutations yielded an improvement of about 100-fold in potency for inhibition of VEGF-dependent cell proliferation by this variant, consistent with the equilibrium binding constant determined from kinetics experiments at 37 degrees C. Using X-ray crystallography, we determined a high-resolution structure of the complex between VEGF and the affinity-matured Fab fragment. The overall features of the binding interface seen previously with wild-type are preserved, and many contact residues are maintained in precise alignment in the superimposed structures. However, locally, we see evidence for improved contacts between antibody and antigen, and two mutations result in increased van der Waals contact and improved hydrogen bonding. Site-directed mutants confirm that the most favorable improvements as judged by examination of the complex structure, in fact, have the greatest impact on free energy of binding. In general, the final antibody has improved affinity for several VEGF variants as compared with the parental antibody; however, some contact residues on VEGF differ in their contribution to the energetics of Fab binding. The results show that small changes even in a large protein-protein binding interface can have significant effects on the energetics of interaction.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>865-81</ArticlePages>
            <ArticleTitle>Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Y</ForeName>
                </Author>
                <Author>
                    <LastName>Wiesmann</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>Fuh</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>B</ForeName>
                </Author>
                <Author>
                    <LastName>Christinger</LastName>
                    <ForeName>H W</ForeName>
                </Author>
                <Author>
                    <LastName>McKay</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>de Vos</LastName>
                    <ForeName>A M</ForeName>
                </Author>
                <Author>
                    <LastName>Lowman</LastName>
                    <ForeName>H B</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Antibodies, Monoclonal;Antigens;Endothelial Growth Factors;Epitopes;Immunoglobulin Fab Fragments;Lymphokines;Peptide Library;Vascular Endothelial Growth Factor A;Vascular Endothelial Growth Factors;Alanine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Alanine(genetics); Amino Acid Sequence; Animals; Antibodies, Monoclonal(chemistry; genetics; immunology; pharmacology); Antibody Affinity(immunology); Antigens(chemistry; immunology); Binding Sites; Cell Division(drug effects); Crystallography, X-Ray; Endothelial Growth Factors(antagonists &amp; inhibitors; chemistry; immunology; pharmacology); Endothelium, Vascular(cytology; drug effects); Epitopes(chemistry; genetics; immunology); Humans; Hydrogen Bonding; Immunoglobulin Fab Fragments(chemistry; genetics; immunology; pharmacology); Lymphokines(antagonists &amp; inhibitors; chemistry; immunology; pharmacology); Mice; Models, Molecular; Molecular Sequence Data; Mutation(genetics); Peptide Library; Protein Conformation; Thermodynamics; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors</ArticleMeshHeadingsList>
            <Journal>
                <Volume>293</Volume>
                <Issue>4</Issue>
                <Title>Journal of molecular biology</Title>
                <Issn>1089-8638</Issn>
                <MedlineTa>J Mol Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Fab Y0317 epitope on VEGF</EpitopeName>
                <EpitopeStructure>
                    <RegionOnMultiChainMolecule>
                        <ChemicalType>Region on multi-chain protein</ChemicalType>
                        <MoleculeName>VEGF homodimer</MoleculeName>
                        <DiscontinuousResidues>V: F43; W: Y71, K74, Q105, I106, M107, R108, I109, H112, Q113, G114, Q115, H116, I117, G118, E119, M120</DiscontinuousResidues>
                        <Chain1>
                            <Molecule>
                                <GenBankId>P15692.2</GenBankId>
                            </Molecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </Chain1>
                        <Chain2>
                            <Molecule>
                                <GenBankId>P15692.2</GenBankId>
                            </Molecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </Chain2>
                    </RegionOnMultiChainMolecule>
                </EpitopeStructure>
                <LocationOfData>PDB 1CZ8</LocationOfData>
                <EpitopeId>226962</EpitopeId>
                <ReferenceRegion>V: F17; W: Y45, K48, Q79, I80, M81, R82, I83, H86, Q87, G88, Q89, H90, I91, G92, E93, M94</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope residues were calculated from [PDB: 1CZ8] as the antigen residues at 4Ã… atomic distance from the antibody. The epitope is located on both chains of a VEGF homodimer.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 8</LocationOfData>
                        <BCellId>1708372</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>262</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>53000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 8</LocationOfData>
                        <BCellId>1708373</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>263</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.0000074</QuantitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4, Table 10 and PDB 1CZ8</LocationOfData>
                        <BCellId>1708356</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.4</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Y0317 Fab on VEGF was determined from the crystal structure of the complex. The final model consists of two Fab fragments bound to the symmetrical poles of the VEGF dimer.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1CZ8</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>VW</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Antigen residues interacting with antibody, paratope residues and contacts are not provided in the reference. This structure is very similar to the structure of VEGF antigen with Fab-12 variant Y0192, the Fab of the wild-type humanized murine anti-VEGF mAb A4.6.1 [PDB: 1BJ1]. The Y0317 variant differs from the Y0192 variant at four amino acids of the heavy chain: T28D, N31H, H101Y, and S105T. The mutation H101Y introduces two additional hydrogen bonds between the antigen and the Fab and is responsible for increasing the antibody-antigen binding affinity by 14-fold.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>V: ; W: ;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: ; L: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>V: F17; W: Y45, K48, Q79, I80, M81, R82, I83, H86, Q87, G88, Q89, H90, I91, G92, E93, M94</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: T30, H31, Y32, G33, W50, N52, T53, Y54, T59, Y99, P100, Y101, Y102, Y103, G104, S106, W108, (SO4)991; L: V94, W96</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>909.6</ContactAreaForAntigen>
                                <ContactAreaForAntibody>864.4</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 9 and Figure 2</LocationOfData>
                        <BCellId>1708357</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>304</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.0198</QuantitativeMeasurement>
                            <AssayComments>The in vitro affinity-matured anti-VEGF monoclonal antibody (Y0317, IgG form) shows stronger binding to the epitope and a different fine specificity compared with the humanized parental anti-VEGF monoclonal antibody (Fab12, IgG form). The residues that profoundly decrease binding of Fab12 (IgG form) to VEGF are shown to be M81, R82, I83 and G92 by alanine scanning analysis by ELISA at 37ÂºC, whereas only residues M81 and G92 are critical for Y0317 (IgG form) binding. In fact, the Kd of the Y0317 Fab is 19.8 Â± 4.3 pM compared with 433 Â± 116 pM for Fab12 (in a radiolabelled VEGF binding assay at 23 Â°C).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 871 and Figure 3</LocationOfData>
                        <BCellId>1708375</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The Fab fragment of the Y0317 variant is stated to be more potent than the wild-type Fab in its ability to inhibit VEGF mitogenic activity on human umbilical vein endothelial cells.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 8</LocationOfData>
                        <BCellId>1708358</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF homodimer</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 Î¼g of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab 12 and affinity-matured through complementarity-determining region (CDR) mutation. The high affinity variant Y0317, which contains six mutations from the parental antibody, was selected.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.14</QuantitativeMeasurement>
                            <AssayComments>Affinity measured by SPR at 37ÂºC showed a 140-fold improvement in the affinity of the variant over that of the humanized parental Fab 12 when measured for binding to VEGF(165) and a 120-fold improvement in binding to VEGF(109).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab-12 variant Y0317</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Y0317</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1CZ8_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1CZ8_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF homodimer</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

